TCR2 Therapeutics (TCR2 Therapeutics) 3-Year Dividend Growth Rate : 0.00% (As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

What is TCR2 Therapeutics 3-Year Dividend Growth Rate?

TCR2 Therapeutics's Dividends per Share for the three months ended in Mar. 2023 was $0.00.

The historical rank and industry rank for TCR2 Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:

TCRR's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.15
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

TCR2 Therapeutics's Dividend Payout Ratio for the three months ended in Mar. 2023 was 0.00. As of today, TCR2 Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of TCR2 Therapeutics's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, TCR2 Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TCR2 Therapeutics's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TCR2 Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where TCR2 Therapeutics's 3-Year Dividend Growth Rate falls into.

TCR2 Therapeutics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

TCR2 Therapeutics (NAS:TCRR) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

TCR2 Therapeutics's Dividend Payout Ratio for the quarter that ended in Mar. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2023 )	/	EPS without NRI (Q: Mar. 2023 )
	=	0	/	-1.03
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TCR2 Therapeutics 3-Year Dividend Growth Rate Related Terms>

TCR2 Therapeutics (TCR2 Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCR2 Therapeutics Inc (NAS:TCRR) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Binney Street, Suite 710, Cambridge, MA, USA, 02142

Website

https://www.tcr2.com

TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its proprietary, first-in-class TCR Fusion Construct T cells (TRuC-T cells). The company's TRuC-T cells specifically recognize and kill cancer cells by harnessing the entire TCR signaling complex, independent of human leukocyte antigens, which are effective in patients with solid tumors.

Executives

Kevin C Tang	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Ansbert Gadicke	director, 10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116
Mpm Asset Management Llc	10 percent owner	399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116
Tang Capital Management Llc	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp	10 percent owner	4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Shawn Tomasello	director	C/O PHARMACYCLICS, INC, 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Priti Hegde	director	TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Rosemary Harrison	officer: Chief Business & Strategy	C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9
Garry E Menzel	director, officer: President & CEO	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Peter Olagunju	officer: Chief Technical Officer	TCR2 THERAPEUTICS INC., 100 BINNEY STREET, SUITE 710, CAMBRIDGE MA 02142
Alfonso Quintas Cardama	officer: Chief Medical Officer	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Angela Justice	officer: Chief People Officer	310 SEVEN SPRINGS WAY, SUITE 500, BRENTWOOD TN 37027
Eric Sullivan	officer: Chief Financial Officer	GOODWIN PROCTER LLP, 53 STATE ST, BOSTON MA 02109
Mayur Ian Somaiya	officer: Chief Financial Officer	TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Axel Hoos	director	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142